The board of directors of GoFintech Innovation Limited announces that Dr. LIU Zhiwei ("Dr. Liu") has resigned as an executive Director, the chairman of the Board (the "Chairman") and the authorised representative of the Company. The Board hereby announces that with effect from 28 February 2024, Mr. CHAN Kin Sang ("Mr. Chan"), an independent non-executive Director, has been appointed as the Chairman and an Authorised Representative. Mr. Chan, aged 72, was appointed as an independent non-executive Director and a member of the audit committee of the Board in July 2014. He was further appointed as a member of each of the Nomination
Committee and the Remuneration Committee in December 2022. Mr. Chan is currently a Notary Public, a China-Appointed Attesting Officer and a senior partner of Kwan & Chow, Solicitors (a law firm which provides
various services including corporate matters and litigation). Mr. Chan obtained a bachelor's degree in Laws from the University of Hong Kong in 1979 and a postgraduate certificate in Laws from the University of Hong
Kong in 1980. He has been a practising solicitor in Hong Kong since April 1982 and has been admitted as a Notary Public since April 1997 and a China-appointed Attesting Officer since January 2000 and a Greater Bay
Area lawyer since December 2023. Mr. Chan has also been a Fellow of The Hong Kong Institute of Directors since August 2004. Mr. Chan is currently a non-executive director of Sino Harbour Holdings Group Limited . He is also an independent non-executive director of Huakang Biomedical Holdings Company Limited (a company listed on the GEM board of the Stock Exchange, stock code: 8622) and Pak Tak International Limited. Over the past three years, Mr. Chan was a chairman of the Appeal Tribunal (Buildings Ordinance - Chapter 123 of the Laws of Hong Kong) from February 2007 to November 2021. The Board hereby announces that with effect from 28 February 2024, Mr. HUA Yang ("Mr. Hua") has been re-designated from an executive Director to a non-executive Director. Mr. Hua, aged 48, was appointed as an executive Director, a member of each of the Nomination Committee and the Remuneration Committee in March 2023. He was appointed as the Chief Executive Officer in January 2023. He has extensive experience in assets management, equity investment, insurance, and business administration. He was a co-founder and a partner of Source Capital Management Co. Ltd., the first insurance-company-backed private equity investment fund approved by the China Insurance Regulatory Commission,from March 2015 to June 2022. Mr. Hua joined the Group in October 2017 as a non-executive Director and was re-designated as an executive Director and was the Chief Executive Officer between March 2018 to April 2020. Mr. Hua was a managing director of a subsidiary of the Group from April 2020 to January 2023. Prior to joining the Group, Mr. Hua was the general manager of Sun Life Everbright Asset Management Co. Ltd. from March 2012 to March 2015. During the period from 1997 to 2012, he had held various senior positions with insurance and securities companies and had completed various initial public offering projects and share placing projects, as well as corporate bonds issuance for a number of companies. Mr. Hua graduated with a bachelor's degree in Economics and Management from Beijing Forestry University in 1997. He also obtained an executive master's degree in Business Administration (EMBA) from Cheung Kong Graduate School of Business in 2005. The Board hereby announces the following changes in composition of Board committees with effect from 28 February 2024: Dr. Liu has resigned as the chairman of the nomination committee of the Board (the "Nomination Committee") and a member of the remuneration committee of the Board (the "Remuneration Committee"); Mr. Chan has been appointed as the chairman of the Nomination Committee; Mr. Hua has resigned as a member of each of the Nomination Committee and the Remuneration Committee; and Ms. SUN Qing, an executive Director, has been appointed as a member of each of the Nomination Committee and the Remuneration Committee.